FDA PMA FDA Class 3 Approved 🇺🇸 United States

Somatic Gene Mutation Detection System

PMA: P110020 · Supplement: S016 · Decision Nov 7, 2016
Classifications
1
FEI Numbers
11
Registration Numbers
11

Basic Information

Device Name
Somatic Gene Mutation Detection System
Trade Name
Roche cobas DNA Sample Preparation Kit, COBAS 4800 BRAF V600 MUTATION TEST
PMA Number
P110020
Supplement Number
S016
Device Class
FDA Class 3
Product Code
OWD
Generic Name
Somatic gene mutation detection system
Medical Specialty
Unknown
Advisory Committee
Pathology
Decision
Approved
Decision Code
APPR
Decision Date
November 7, 2016
Date Received
June 30, 2016
Supplement Type
Normal 180 Day Track
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

Approval for the cobas® 4800 BRAF V600 Mutation Test. The cobas® 4800 BRAF V600 Mutation Test is an in vitro diagnostic device intended for the qualitative detection of BRAF V600E mutation in DNA extracted from formalin-fixed, paraffin-embedded human melanoma tissue. The cobas® 4800 BRAF V600 Mutation Test is a real-time PCR test on the cobas® 4800 System, and is intended to be used as an aid in selecting melanoma patients for treatment with the targeted therapies listed in the table below, in accordance with the approved therapeutic product labeling: Therapeutic Therapeutic Indication Test ResultZELBORAF® (vemurafenib) BRAF V600E Mutation DetectedCOTELLIC® (cobimetinib), in combination with ZELBORAF® (vemurafenib) BRAF V600E or V600K* Mutation Detected* *Due to cross-reactivity by the cobas® 4800 BRAF V600 Mutation Test, the clinical trial for cobimetinib, in combination with vemurafenib, included some patients whose tumor carried the BRAF V600K mutation.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
OWD Somatic Gene Mutation Detection System